Skip to main content

Detailed Program

Monday, October 28, 2024

  • 07:00

    Registration opens

  • 08:00-08:15

    Welcome and Introductory Comments
    Welcome from: Jon Odorico, Doug Melton and James Markmann

  • 08:15-09:30

    Session 1
    Insights from Islet Biology for Making Stem Cell-Derived Islets
    Moderator: Albert Hwa

  • 08:15-08:30

    Insights into islet biology from the human pancreas and beyond
    Alvin Powers, Vanderbilt University, United States

  • 08:30-08:45

    Insights into beta cell development from stem cells
    Matthias Hebrok, Technical University of Munich, Germany

  • 08:45-09:00

    Using stem cell islets to gain insights into human pancreas development
    Danwei Huangfu, Memorial Sloan Kettering, United States

  • 09:00-09:15

    Using human pancreas slices to understand islet physiology and function
    Joana Collares Pereira Almaca, University of Miami School of Medicine, United States

  • 09:15-09:30

    Panel Discussion

  • 09:30-10:00

    Coffee Break

  • 10:00-11:15

    Session 2
    Optimizing Differentiation to Stem Cell Beta Cells
    Moderator: Cristina Nostro

  • 10:00-10:15

    Tuning developmental signaling during stem cell-derived islet differentiation
    Nathaniel Hogrebe, Washington University School of Medicine, United States

  • 10:15-10:30

    Functional maturation of stem cell islets
    Diego Balboa, University of Helsinki, Finland

  • 10:30-10:45

    Origin and development of off-target cell populations arising during stem cell to islet differentiation
    Christian Honoré, Cell Therapy R&D, Novo Nordisk A/S, Denmark

  • 10:45-11:00

    Scalable generation of 3D stem cell islet organoids or Hallmarks and triggers of beta cell maturation
    Juan Alvarez-Dominguez, University of Pennsylvania, United States

  • 11:00-11:15

    Panel Discussion

  • 11:15-11:30

    Stretch Break

  • 11:30-12:45

    Session 3
    Immunology of T1D
    Moderator: Lorenzo Piemonti

  • 11:30-11:45

    Type 1 diabetes as a disease of the beta-cell
    Bart Roep, Leiden University Medical Center, Netherlands

  • 11:45-12:00

    Neoantigens and autoimmunity triggering mechanisms
    Eddie James, Benroya Research Institute, United States

  • 12:00-12:15

    Tracking antigen-specific T cell receptors during T1D progression
    Maki Nakayama, University of Colorado, United States

  • 12:15-12:30

    Modeling the immune infiltration of human stem cell-derived islets in vivo
    Remi Creusot, Columbia University, United States

  • 12:30-12:45

    Panel Discussion

  • 12:45-13:45

    Lunch Break, Poster Viewing & Group Photo

  • 13:45-14:15

    Keynote Address
    Introduction: Doug Melton

  • 13:45-14:15

    Disease Modifying Therapies and rationale for combining with stem cell islets
    Tom Kay, St Vincent's Hospital, Australia

  • Abstract 1

    Anja Ivis
    Strategies for preventing the formation of cytotoxic IAPP amyloid in human stem cell-derived islets

  • Abstract 2

    Hong Qian
    Development of a biovascular pancreas to deliver stem cell-derived islets as a therapy for type 1 diabetes

  • Abstract 3

    Anup Nair
    Modeling the effects of early hyperinsulinemia due to the R1420H SUR1 mutation using isogenic iPSC derived pancreatic Islets

  • Abstract 4

    Sophia Kioulaphides
    Human stem cell-derived beta-cells delivered with vasculogenic hydrogels reverse hyperglycemia in diabetic immunodeficient mice

  • Abstract 5

    Veronica Cochrane
    SC-beta cell MafA expression: for better or worse

  • Abstract 6

    Paraish Misra
    Islet versus enterochromaffin lineage allocation of hPSC-derived pancreatic progenitors can be modulated at both pre-progenitor and post-progenitor stages

  • 15:15-15:45

    Coffee Break

  • Abstract 1

    Pere Catala
    Ultrafast Volumetric Bioprinting of an Endocrine Pancreas Using Functional Human iPSC-Derived Islets

  • Abstract 2

    Francesco Campo
    Bio-fabrication of a Human iPSC-based vascularized endocrine pancreas for the treatment of Type 1 Diabetes

  • Abstract 3

    Saleth Dharmaraj
    A perfusable encapsulation device housing Stem cell derived pseudo-islets to treat type-1 diabetes

  • Abstract 4

    Ji Lei
    Identifying optimal engraftment sites for human stem cell-derived islets in a non-Human primate model

  • Abstract 5

    Nicole Wojcik
    Optimization of immunosuppression for beta cell replacement therapy: assessing the tolerability and efficacy of belatacept combined with reduced tacrolimus

  • Abstract 6

    Daniel Tremmel
    Islet vascularized ECM organoid (IVEO) constructs repair isolated islets native environment for successful engraftment and functionality post-transplantation

  • 16:45-18:00

    Session 5
    Immune Evasive Islets
    Moderator: Holger Russ

  • 16:45-17:00

    PIDO induced islet immune protection from allo and xeno immunity
    Jacques Galipeau, University of Wisconsin School of Medicine and Public Health, United States

  • 17:00-17:15

    Hypoimmune Stem Cell Islets
    Sonja Schrepfer, Sana Biotechnology, United States

  • 17:15-17:30

    Genome editing of stem cell islets for hypoimmunity
    Audrey Parent, University of California San Francisco Diabetes Center, United States

  • 17:30-17:45

    Combinatorial genome engineering strategy for antigen specific protection of stem cell derived beta cells by CAR Tregs
    Jessie Barra, University of Florida College of Medicine, United States

  • 17:45-18:00

    Panel Discussion

  • 18:00-18:05

    Day One Wrap Up
    Day One Wrap Up: Jon Odorico

  • 18:05-19:30

    Networking Reception
Tuesday, October 29, 2024

  • 07:00

    Registration opens

  • 07:30-08:45

    Session 6
    Beta Cell Replacement Clinical Trials Update
    Moderator: Jon Odorico

  • 07:30-07:50

    Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes: Data from the Phase 1/2 FORWARD Study
    Michael Rickels, University of Pennsylvania, United States

  • 07:50-08:10

    CD40L immunosuppression and Sernova Islet transplant trials
    Piotr Witkowski, Transplant Institute University of Chicago Medicine, United States

  • 08:10-08:30

    Parathyroid gland supplemented human islet engraftment and function in humans
    Peter Stock, University of California San Francisco, United States

  • 08:30-08:45

    Panel Discussion

  • 08:45-09:00

    Stretch Break

  • 09:00-10:15

    Session 7
    Immunomodulation/Encapsulation
    Moderator: James Markmann

  • 09:00-09:15

    Overview of Immunomodulation Strategies
    Alessandro Grattoni, Houston Methodist Hospital, United States

  • 09:15-09:30

    Role of EVs in Immunomodulation of stem cell islets
    Edward Phelps, University of Florida, United States

  • 09:30-09:45

    CD40L immunotherapy to protect transplanted islets
    Norma Kenyon, University of Miami Miller School of Medicine, United States

  • 09:45-10:00

    The Good and Bad of Humanized Mouse Models
    Michael Brehm, University of Massachusetts Chan Medical School, United States

  • 10:00-10:15

    Panel Discussion

  • 10:15-10:45

    Coffee Break

  • 10:45-12:00

    Session 8
    Overcoming challenges to broader clinical application of stem cell-derived islets
    Moderator: Esther Latres

  • 10:45-11:00

    Successful cryopreservation of intact stem cell islets
    Joseph Sushil Rao, University of Minnesota, United States

  • 11:00-11:15

    Delivering insulin-producing cells without immunosuppression
    Minglin Ma, Cornell University, United States

  • 11:15-11:30

    Novel scale up technologies
    Kevin Alessandri, TreeFrog Therapeutics, United States

  • 11:30-12:00

    Panel Discussion

  • 12:00-13:00

    Lunch Break & Poster Viewing

  • Abstract 1

    Sonja Schrepfer
    Hypoimmune Islet Cells Mediate Insulin Independence After Allogeneic Transplantation Without Immunosuppression

  • Abstract 2

    Kfir Molakandov
    IsletRxPlus, CD26− and CD49A+ enriched hESC-derived Islet cells, improves safety and identity profile in diabetic mice at multiple implantation sites.

  • Abstract 3

    Caterra Leavens
    The beta cell “invisibility cloak” – Developing stem cell-derived pancreatic islets that are protected from the immune system

  • Abstract 4

    Mina Seedhom
    Study of interactions between human immune systems and SC-islets from T1D individuals in a novel NSG MHC-DKO Tg(hIL15) mouse

  • 13:30-15:05

    Session 10
    Future Opportunities And Barriers for Broad Clinical Application

  • 13:30-14:15

    Panel 1
    Manufacturing, Scale Up, Regulatory
    Moderator: Jeffrey Millman

    Felicia Pagliuca, Vertex Pharmaceuticals, Inc. United States
    Heather Lombardi, FDA - CBER, United States
    Tom Bollenbach, BiofabUSA, United States
    Kevin Alessandri, TreeFrog Therapeutics, United States

  • 14:20-15:05

    Panel 2
    Eligibility Criteria and Future Clinical Trial Design
    Moderator: Eelco DeKoning

    Lorenzo Piemonti, Universita Vita-Salute San Raffaele, Italy
    Trevor Reichman, U Toronto, Canada
    Marjana Marinac, Breakthrough T1D, United States
    Norma Kenyon, University of Miami Miller School of Medicine, United States

  • 15:05-15:10

    Closing
    Closing from: Jon Odorico